Abstract
Objective To examine the influence of titration schedule and maintenance dose on the incidence and type of treatment-emergent adverse events (TEAEs) associated with adjunctive eslicarbazepine acetate (ESL). Methods Data from three randomized, double-blind, placebo-controlled trials were analyzed. Patients with refractory partial-onset seizures were randomized to maintenance doses of ESL 400, 800, or 1200 mg QD (dosing was initiated at 400 or 800 mg QD) or placebo. The incidence of TEAEs was analyzed during the double-blind period (2‐week titration phase; 12-week maintenance phase), according to the randomized maintenance dose and the titration schedule. Results 1447 patients were included in the analysis. During the first week of treatment, 62% of patients taking ESL 800 mg QD had ≥1 TEAE, vs 35% of those taking 400 mg QD and 32% of the placebo group; dizziness, somnolence, nausea, and headache were numerically more frequent in patients taking ESL 800 mg than those taking ESL 400 mg QD. During the double-blind period, the incidences of common TEAEs were lower in patients who initiated ESL at 400 mg vs 800 mg QD. For the 800 and 1200 mg QD maintenance doses, rates of TEAEs leading to discontinuation were lower in patients who began treatment with 400 mg than in those who began taking ESL 800 mg QD. Conclusions Initiation of ESL at 800 mg QD is feasible. However, initiating treatment with ESL 400 mg QD for 1 or 2 weeks is recommended, being associated with a lower incidence of TEAEs, and related discontinuations. For some patients, treatment may be initiated at 800 mg QD, if the need for more immediate seizure reduction outweighs concerns about increased risk of adverse reactions during initiation.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1-8 |
| Number of pages | 8 |
| Journal | Epilepsy Research |
| Volume | 139 |
| DOIs | |
| State | Published - Jan 1 2018 |
Fingerprint
Keywords
- Eslicarbazepine acetate
- Partial-onset seizures
- Titration schedule
- Tolerability
ASJC Scopus subject areas
- Neurology
- Clinical Neurology
Cite this
Influence of titration schedule and maintenance dose on the tolerability of adjunctive eslicarbazepine acetate : An integrated analysis of three randomized placebo-controlled trials. / Krauss, Gregory; Biton, Victor; Harvey, Jay H.; Elger, Christian; Trinka, Eugen; Soares da Silva, Patrício; Gama, Helena; Cheng, Hailong; Grinnell, Todd; Blum, David.
In: Epilepsy Research, Vol. 139, 01.01.2018, p. 1-8.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Influence of titration schedule and maintenance dose on the tolerability of adjunctive eslicarbazepine acetate
T2 - An integrated analysis of three randomized placebo-controlled trials
AU - Krauss, Gregory
AU - Biton, Victor
AU - Harvey, Jay H.
AU - Elger, Christian
AU - Trinka, Eugen
AU - Soares da Silva, Patrício
AU - Gama, Helena
AU - Cheng, Hailong
AU - Grinnell, Todd
AU - Blum, David
PY - 2018/1/1
Y1 - 2018/1/1
N2 - Objective To examine the influence of titration schedule and maintenance dose on the incidence and type of treatment-emergent adverse events (TEAEs) associated with adjunctive eslicarbazepine acetate (ESL). Methods Data from three randomized, double-blind, placebo-controlled trials were analyzed. Patients with refractory partial-onset seizures were randomized to maintenance doses of ESL 400, 800, or 1200 mg QD (dosing was initiated at 400 or 800 mg QD) or placebo. The incidence of TEAEs was analyzed during the double-blind period (2‐week titration phase; 12-week maintenance phase), according to the randomized maintenance dose and the titration schedule. Results 1447 patients were included in the analysis. During the first week of treatment, 62% of patients taking ESL 800 mg QD had ≥1 TEAE, vs 35% of those taking 400 mg QD and 32% of the placebo group; dizziness, somnolence, nausea, and headache were numerically more frequent in patients taking ESL 800 mg than those taking ESL 400 mg QD. During the double-blind period, the incidences of common TEAEs were lower in patients who initiated ESL at 400 mg vs 800 mg QD. For the 800 and 1200 mg QD maintenance doses, rates of TEAEs leading to discontinuation were lower in patients who began treatment with 400 mg than in those who began taking ESL 800 mg QD. Conclusions Initiation of ESL at 800 mg QD is feasible. However, initiating treatment with ESL 400 mg QD for 1 or 2 weeks is recommended, being associated with a lower incidence of TEAEs, and related discontinuations. For some patients, treatment may be initiated at 800 mg QD, if the need for more immediate seizure reduction outweighs concerns about increased risk of adverse reactions during initiation.
AB - Objective To examine the influence of titration schedule and maintenance dose on the incidence and type of treatment-emergent adverse events (TEAEs) associated with adjunctive eslicarbazepine acetate (ESL). Methods Data from three randomized, double-blind, placebo-controlled trials were analyzed. Patients with refractory partial-onset seizures were randomized to maintenance doses of ESL 400, 800, or 1200 mg QD (dosing was initiated at 400 or 800 mg QD) or placebo. The incidence of TEAEs was analyzed during the double-blind period (2‐week titration phase; 12-week maintenance phase), according to the randomized maintenance dose and the titration schedule. Results 1447 patients were included in the analysis. During the first week of treatment, 62% of patients taking ESL 800 mg QD had ≥1 TEAE, vs 35% of those taking 400 mg QD and 32% of the placebo group; dizziness, somnolence, nausea, and headache were numerically more frequent in patients taking ESL 800 mg than those taking ESL 400 mg QD. During the double-blind period, the incidences of common TEAEs were lower in patients who initiated ESL at 400 mg vs 800 mg QD. For the 800 and 1200 mg QD maintenance doses, rates of TEAEs leading to discontinuation were lower in patients who began treatment with 400 mg than in those who began taking ESL 800 mg QD. Conclusions Initiation of ESL at 800 mg QD is feasible. However, initiating treatment with ESL 400 mg QD for 1 or 2 weeks is recommended, being associated with a lower incidence of TEAEs, and related discontinuations. For some patients, treatment may be initiated at 800 mg QD, if the need for more immediate seizure reduction outweighs concerns about increased risk of adverse reactions during initiation.
KW - Eslicarbazepine acetate
KW - Partial-onset seizures
KW - Titration schedule
KW - Tolerability
UR - http://www.scopus.com/inward/record.url?scp=85032967495&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85032967495&partnerID=8YFLogxK
U2 - 10.1016/j.eplepsyres.2017.10.021
DO - 10.1016/j.eplepsyres.2017.10.021
M3 - Article
C2 - 29127848
AN - SCOPUS:85032967495
VL - 139
SP - 1
EP - 8
JO - Epilepsy Research
JF - Epilepsy Research
SN - 0920-1211
ER -